The involvement of the sigma-1 receptor in neurodegeneration and neurorestoration
- PMID: 25704015
- DOI: 10.1016/j.jphs.2014.11.011
The involvement of the sigma-1 receptor in neurodegeneration and neurorestoration
Abstract
The sigma-1 receptor (Sig-1R) is a single 25 kD polypeptide and a chaperone protein immersed in lipid rafts of the endoplasmic reticulum (ER) where it interacts with mitochondria at the mitochondria-associated ER membrane domain (MAM). Upon activation, the Sig-1R binds to the inositol trisphosphate receptor (IP3R), and modulates cellular calcium (Ca(2+)) homeostasis. Also, the activated Sig-1R modulates plasma membrane receptor and ion channel functions, and may regulate cellular excitability. Further, the Sig-1R promotes trafficking of lipids and proteins essential for neurotransmission, cell growth and motility. Activation of the Sig-1R provides neuroprotection and is neurorestorative in cellular and animal models of neurodegenerative diseases and brain ischaemia. Neuroprotection appears to be due to inhibition of cellular Ca(2+) toxicity and/or inflammation, and neurorestoration may include balancing abberant neurotransmission or stimulation of synaptogenesis, thus remodelling brain connectivity. Single nucleotide polymorphisms and mutations of the SIGMAR1 gene worsen outcome in Alzheimer's disease and myotrophic lateral sclerosis supporting a role of Sig-1R in neurodegenerative disease. The combined neuroprotective and neurorestorative actions of the Sig-1R, provide a broad therapeutic time window of Sig-1R agonists. The Sig-1R is therefore a strong therapeutic target for the development of new treatments for neurodegenerative diseases and stroke.
Keywords: Lipid raft; Neuroprotection; Neurorestoration; Sigma-1 receptor; Stroke.
Copyright © 2014 Japanese Pharmacological Society. Production and hosting by Elsevier B.V. All rights reserved.
Similar articles
-
The Role of Sigma-1 Receptor, an Intracellular Chaperone in Neurodegenerative Diseases.Curr Neuropharmacol. 2018;16(1):97-116. doi: 10.2174/1570159X15666170529104323. Curr Neuropharmacol. 2018. PMID: 28554311 Free PMC article. Review.
-
Emerging Benefits: Pathophysiological Functions and Target Drugs of the Sigma-1 Receptor in Neurodegenerative Diseases.Mol Neurobiol. 2021 Nov;58(11):5649-5666. doi: 10.1007/s12035-021-02524-5. Epub 2021 Aug 12. Mol Neurobiol. 2021. PMID: 34383254 Review.
-
Roles of sigma-1 receptors on mitochondrial functions relevant to neurodegenerative diseases.J Biomed Sci. 2017 Sep 16;24(1):74. doi: 10.1186/s12929-017-0380-6. J Biomed Sci. 2017. PMID: 28917260 Free PMC article. Review.
-
At the Crossing of ER Stress and MAMs: A Key Role of Sigma-1 Receptor?Adv Exp Med Biol. 2020;1131:699-718. doi: 10.1007/978-3-030-12457-1_28. Adv Exp Med Biol. 2020. PMID: 31646531 Review.
-
Role of Sigma-1 Receptor in Cocaine Abuse and Neurodegenerative Disease.Adv Exp Med Biol. 2017;964:163-175. doi: 10.1007/978-3-319-50174-1_12. Adv Exp Med Biol. 2017. PMID: 28315271 Review.
Cited by
-
Contribution of Lysosome and Sigma Receptors to Neuroprotective Effects of Memantine Against Beta-Amyloid in the SH-SY5Y Cells.Adv Pharm Bull. 2020 Jul;10(3):452-457. doi: 10.34172/apb.2020.055. Epub 2020 May 11. Adv Pharm Bull. 2020. PMID: 32665905 Free PMC article.
-
Recent Advances in Drug Therapy for Parkinson's Disease.Intern Med. 2023 Jan 1;62(1):33-42. doi: 10.2169/internalmedicine.8940-21. Epub 2022 Feb 1. Intern Med. 2023. PMID: 35110492 Free PMC article. Review.
-
Sigma-1 Receptor-Modulated Neuroinflammation in Neurological Diseases.Front Cell Neurosci. 2018 Sep 20;12:314. doi: 10.3389/fncel.2018.00314. eCollection 2018. Front Cell Neurosci. 2018. PMID: 30294261 Free PMC article. Review.
-
A precision medicine framework using artificial intelligence for the identification and confirmation of genomic biomarkers of response to an Alzheimer's disease therapy: Analysis of the blarcamesine (ANAVEX2-73) Phase 2a clinical study.Alzheimers Dement (N Y). 2020 Apr 19;6(1):e12013. doi: 10.1002/trc2.12013. eCollection 2020. Alzheimers Dement (N Y). 2020. PMID: 32318621 Free PMC article.
-
New therapeutics beyond amyloid-β and tau for the treatment of Alzheimer's disease.Acta Pharmacol Sin. 2021 Sep;42(9):1382-1389. doi: 10.1038/s41401-020-00565-5. Epub 2020 Dec 2. Acta Pharmacol Sin. 2021. PMID: 33268824 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous